AU2016320905B2 - Compositions and methods for prevention and treatment of corneal haze and scarring - Google Patents

Compositions and methods for prevention and treatment of corneal haze and scarring Download PDF

Info

Publication number
AU2016320905B2
AU2016320905B2 AU2016320905A AU2016320905A AU2016320905B2 AU 2016320905 B2 AU2016320905 B2 AU 2016320905B2 AU 2016320905 A AU2016320905 A AU 2016320905A AU 2016320905 A AU2016320905 A AU 2016320905A AU 2016320905 B2 AU2016320905 B2 AU 2016320905B2
Authority
AU
Australia
Prior art keywords
hgf
scarring
corneal
amino acid
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016320905A
Other languages
English (en)
Other versions
AU2016320905A1 (en
Inventor
Sunil Chauhan
Reza Dana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Eye and Ear
Original Assignee
Massachusetts Eye and Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye and Ear Infirmary filed Critical Massachusetts Eye and Ear Infirmary
Publication of AU2016320905A1 publication Critical patent/AU2016320905A1/en
Application granted granted Critical
Publication of AU2016320905B2 publication Critical patent/AU2016320905B2/en
Priority to AU2021286438A priority Critical patent/AU2021286438B2/en
Priority to AU2025201563A priority patent/AU2025201563A1/en
Assigned to MASSACHUSETTS EYE AND EAR INFIRMARY reassignment MASSACHUSETTS EYE AND EAR INFIRMARY Request for Assignment Assignors: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2016320905A 2015-09-11 2016-09-09 Compositions and methods for prevention and treatment of corneal haze and scarring Active AU2016320905B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021286438A AU2021286438B2 (en) 2015-09-11 2021-12-17 Compositions and methods for prevention and treatment of corneal haze and scarring
AU2025201563A AU2025201563A1 (en) 2015-09-11 2025-03-04 Compositions and methods for prevention and treatment of corneal haze and scarring

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562217611P 2015-09-11 2015-09-11
US62/217,611 2015-09-11
PCT/US2016/050945 WO2017044743A1 (en) 2015-09-11 2016-09-09 Compositions and methods for prevention and treatment of corneal haze and scarring

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021286438A Division AU2021286438B2 (en) 2015-09-11 2021-12-17 Compositions and methods for prevention and treatment of corneal haze and scarring

Publications (2)

Publication Number Publication Date
AU2016320905A1 AU2016320905A1 (en) 2018-04-05
AU2016320905B2 true AU2016320905B2 (en) 2021-10-07

Family

ID=58240852

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016320905A Active AU2016320905B2 (en) 2015-09-11 2016-09-09 Compositions and methods for prevention and treatment of corneal haze and scarring
AU2021286438A Active AU2021286438B2 (en) 2015-09-11 2021-12-17 Compositions and methods for prevention and treatment of corneal haze and scarring
AU2025201563A Pending AU2025201563A1 (en) 2015-09-11 2025-03-04 Compositions and methods for prevention and treatment of corneal haze and scarring

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021286438A Active AU2021286438B2 (en) 2015-09-11 2021-12-17 Compositions and methods for prevention and treatment of corneal haze and scarring
AU2025201563A Pending AU2025201563A1 (en) 2015-09-11 2025-03-04 Compositions and methods for prevention and treatment of corneal haze and scarring

Country Status (7)

Country Link
US (4) US10449234B2 (https=)
EP (2) EP3347034B1 (https=)
JP (4) JP6929273B2 (https=)
AU (3) AU2016320905B2 (https=)
CA (1) CA2999511C (https=)
ES (1) ES2983338T3 (https=)
WO (1) WO2017044743A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2999511C (en) 2015-09-11 2024-01-23 The Schepens Eye Research Institute, Inc. Compositions and methods for prevention and treatment of corneal haze and scarring
WO2019155833A1 (ja) * 2018-02-07 2019-08-15 学校法人日本医科大学 改良型アデノ随伴ウイルスベクター
EP3863715A4 (en) * 2018-10-09 2022-08-24 The Board of Trustees of the Leland Stanford Junior University MODIFIED FIBROBLASTIC GROWTH FACTOR VARIANTS COMBINED WITH MODIFIED HEPATOCYTE GROWTH FACTOR VARIANTS FOR THERAPY
WO2020185689A1 (en) * 2019-03-08 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Multilayer drug delivery coating for contact lens
EP3962511A4 (en) * 2019-04-29 2023-01-18 The Board of Trustees of the Leland Stanford Junior University METHODS OF OCULAR TREATMENT USING A GENETICALLY MODIFIED HEPATOCYTE GROWTH FACTOR DIMERIC FRAGMENT
EP4574211A3 (en) 2021-05-14 2025-09-10 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703047A (en) * 1992-09-21 1997-12-30 Board Of Regents, The University Of Texas System Methods and treatments for corneal healing with growth factors
US5776464A (en) * 1994-03-18 1998-07-07 Nakamura; Toshikazu Agent for relieving side effects caused by immunosuppressants
US20070167935A1 (en) * 2007-01-19 2007-07-19 Serdarevic Olivia N Methods and compositions for optimizing the outcomes of refractive laser surgery of the cornea
EP2025342A1 (en) * 2006-04-20 2009-02-18 Osaka University Therapeutic agent or development inhibitor of polyglutamine disease
US20110269944A1 (en) * 2006-04-20 2011-11-03 Toshikazu Nakamura Hgf precursor protein variant and active protein thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
US5589451A (en) 1992-09-21 1996-12-31 Board Of Regents, The University Of Texas System Methods and treaments for corneal healing with hepatocyte and keratinocyte growth factors
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
AU2745599A (en) 1998-03-05 1999-09-20 Senju Pharmaceutical Co., Ltd. Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy
US20030148950A1 (en) * 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US9556248B2 (en) * 2010-03-19 2017-01-31 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
HRP20191711T1 (hr) 2011-03-14 2019-12-13 Drug Delivery Solutions Ltd Oftalmološki pripravak
US8999938B2 (en) * 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CA2999511C (en) 2015-09-11 2024-01-23 The Schepens Eye Research Institute, Inc. Compositions and methods for prevention and treatment of corneal haze and scarring

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703047A (en) * 1992-09-21 1997-12-30 Board Of Regents, The University Of Texas System Methods and treatments for corneal healing with growth factors
US5776464A (en) * 1994-03-18 1998-07-07 Nakamura; Toshikazu Agent for relieving side effects caused by immunosuppressants
EP2025342A1 (en) * 2006-04-20 2009-02-18 Osaka University Therapeutic agent or development inhibitor of polyglutamine disease
US20110269944A1 (en) * 2006-04-20 2011-11-03 Toshikazu Nakamura Hgf precursor protein variant and active protein thereof
US20070167935A1 (en) * 2007-01-19 2007-07-19 Serdarevic Olivia N Methods and compositions for optimizing the outcomes of refractive laser surgery of the cornea

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANITUA E.; MURUZABAL F.; ALCALDE I.; MERAYO-LLOVES J.; ORIVE G.: "Plasma rich in growth factors (PRGF-Endoret) stimulates corneal wound healing and reduces haze formation after PRK surgery", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD., LONDON., vol. 115, 18 July 2013 (2013-07-18), LONDON., pages 153 - 161, XP028733454, ISSN: 0014-4835, DOI: 10.1016/j.exer.2013.07.007 *
Anonymous: "Facts About Dry Eye", 5 September 2015 (2015-09-05), XP055711861,Retrieved from the Internet:URL:https://web.archive.org/web/20150905104213/https://nei.nih.gov/health/dryeye/dryeye[retrieved on 2020-07-06] *
AZUCENA KAKAZU ET AL, "HGF Protects Corneal Epithelial Cells from Apoptosis by the PI-3K/Akt-1/Bad- but Not the ERK1/2-Mediated Signaling Pathway", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, US, (2004-10-01), vol. 45, no. 10, page 3485 *
KOJIMA T ET AL, "Autologous serum eye drops for the treatment of dry eye diseases", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (2008-09), Database accession no. EMB-2009405412 *
KUNIO MATSUMOTO, HIROSHI FUNAKOSHI, HISAAKI TAKAHASHI, KATSUYA SAKAI: "HGF–Met Pathway in Regeneration and Drug Discovery", BIOMEDICINES, vol. 2, no. 4, pages 275 - 300, XP055412657, DOI: 10.3390/biomedicines2040275 *
Steven E Wilson ET AL: "Lacrimal Gland HGF, KGF, and EGF mRNA Levels Increase after Corneal Epithelial Wounding",Investigative Ophthalmology & Visual Science, vol. 40, no. 10, 1 September 1999 (1999-09-01), pages 2185-2190 *
YE SUN;LI SU;ZHONGXIAO WANG;YI XU;XUN XU: "H-RN, a peptide derived from hepatocyte growth factor, inhibits corneal neovascularization by inducing endothelial apoptosis and arresting the cell cycle", BMC CELL BIOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 14, no. 1, 24 February 2013 (2013-02-24), GB, pages 8, XP021140734, ISSN: 1471-2121, DOI: 10.1186/1471-2121-14-8 *

Also Published As

Publication number Publication date
EP3347034A4 (en) 2019-05-08
HK1258026A1 (en) 2019-11-01
EP4417259A3 (en) 2024-10-23
WO2017044743A1 (en) 2017-03-16
CA2999511C (en) 2024-01-23
US11759499B2 (en) 2023-09-19
US20180256685A1 (en) 2018-09-13
US20210299219A1 (en) 2021-09-30
JP2025181979A (ja) 2025-12-11
AU2021286438A1 (en) 2022-01-20
CA2999511A1 (en) 2017-03-16
JP2018526412A (ja) 2018-09-13
EP3347034B1 (en) 2024-05-29
AU2016320905A1 (en) 2018-04-05
JP2021181472A (ja) 2021-11-25
EP3347034A1 (en) 2018-07-18
EP3347034C0 (en) 2024-05-29
JP6929273B2 (ja) 2021-09-01
US10449234B2 (en) 2019-10-22
AU2021286438B2 (en) 2024-12-05
US20200121758A1 (en) 2020-04-23
AU2025201563A1 (en) 2025-03-27
JP2023179739A (ja) 2023-12-19
ES2983338T3 (es) 2024-10-22
EP4417259A2 (en) 2024-08-21
US20240123032A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
AU2021286438B2 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
Huang et al. Combination of dexamethasone and Avastin® by supramolecular hydrogel attenuates the inflammatory corneal neovascularization in rat alkali burn model
EP3886858B1 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
JP2002515858A (ja) 角膜移植に起因する疾患を処置するための殺菌／浸透性増強（ｂｐｉ）タンパク質
CA3022152C (en) DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR THE TOPICAL OCULAR TREATMENT OF RETINAL NEURODEGENERATIVE DISEASES
KR101214364B1 (ko) 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
KR101214362B1 (ko) Ｆｋ506 결합 단백질 융합 단백질을 함유하는 안과 질환 예방 및 치료용 점안제 조성물
TW202128746A (zh) 融合蛋白在治療年齡相關性黃斑變性中的應用
EP3402511B1 (en) Compositions and methods for treatment of ocular diseases
EP3338792B1 (en) Corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid as active ingredients
KR102023827B1 (ko) 안구 건조증 질환의 치료 및/또는 예방을 위한 짧은 합성 펩티드의 용도
HK40061312B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
HK40061312A (en) Compounds for treatment of eye diseases associated with excessive vascularisation
JPWO2001091779A1 (ja) 角膜創傷治療剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MASSACHUSETTS EYE AND EAR INFIRMARY

Free format text: FORMER OWNER(S): THE SCHEPENS EYE RESEARCH INSTITUTE, INC.